Crystal ball gazing in RA: predicting who will respond to which targeted therapy, so we don't have to do too much expensive trial-and-error.
This is by far the toughest of all RA clairvoyance acts, partly because we have so many treatment options, but mainly because we lack accessible and reliable biomarkers.
Case in point, we start with this biomarker: myeloid predominant synovitis predicts for better response to anti-TNF agents.
DNA methylation profiling: that is so accessible, seriously.
High baseline NK cells level in peripheral blood predicts for response to anti-IL6.
RF and ACPA positivity predicts for good response to T-cell co-stimulation blockade as well as B-cell depletion.